Indian pharma industry on cusp of growth spurt, CPHI Worldwide audience told
Country expected to grow threefold over the next decade due to increased focus on complex generics, biosimilars and specialty products
The Indian pharmaceutical sector is set to expand threefold over the next decade into a $130 billion industry, with most of the growth coming from novel biologics, new molecular entities, vaccines and more integrated API and key starting material production, according to Sriram Shrinivasan, Global Generics Leader and India Health & Lifesciences Leader, EY.
Speaking at the CPHI Worldwide online conference on Tuesday, Shrinivasan said he believed the Indian industry was going to move beyond being a volume-driven industry to a value-focused one.
“To do this, we need to understand that what has made you successful so far is not necessarily going to bring you future success,” he told the conference. “So far, the Indian industry has done generics very well; fast, right, cheap and easy. What they need to do now is explore the world beyond simple generics and look at far more complex generics and specialty products.”
Shrinivasan said India also needed to leverage contract development and manufacturing on a much greater scale.
“Often we notice that contract development and manufacturing still remain in the country of origin. What is important is to try and see how India can capitalise on growth the CDMO market, get into high technology, difficult-to-manufacture products and be able to establish,” he continued.
He said that the third and most important ingredient for future Indian pharma growth was establishing the country as a global R&D innovation hub: “Creating its own molecules, creating its own biologics – that is where the future is.”
Shrinivasan said that over the last three years, the Indian pharmaceutical industry has transformed itself from one that is dependent on medicines to becoming a net exporter and almost a world leader.
“The journey is only half done; there is still a lot more that the Indian pharma industry needs to do, it’s already well underway and it’s going to be the powerhouse to watch out for in the next decade to come,” he said.
He said the Indian pharma industry has grown tenfold in the last 20 years from $4.2 billion in 2000 to $41.7 billion in 2020, driven by its strength in the generic medicines market.
He added that the country was well on the way to medicines self-sufficiency, with the share of ‘Made in India’ drug products in the domestic market at 80% in 2020, compared to just 5% in 1969.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance